(Dublin, OH) Dublin City Council has approved an economic development agreement with Andelyn Biosciences, a pioneering gene therapy development and manufacturing company that plans to expand its Research & Development facilities to Dublin.
The company pairs unique manufacturing capabilities and life-changing research to produce materials for gene therapy clinical studies around the world. It has outgrown its current space in Columbus, with limited options to expand its research activities there. Andelyn Biosciences was established at Nationwide Children’s Hospital and continues to have a close relationship with its world-class Abigail Wexner Research Institute.
The expansion to Dublin will add approximately 70 jobs to the community by the end of 2027. The incentives package includes a seven-year, 20 percent performance incentive on withholdings collected for all employees and a $10,000 facility grant to offset laboratory fit-up costs at its new location.
“Through their leading-edge technologies and solutions for gene-based therapies, Andelyn Biosciences provides cures and hope for families looking for a healthy future,” says Director of Economic Development, Colleen Gilger. “Their expansion to Dublin helps grow the City’s presence in the medical biosciences and health care industries and further builds the Central Ohio region as a biotechnology hub for life-changing research and therapeutics.”
The incentive is contingent upon the company signing a minimum ten-year lease within City of Dublin corporation limits of at least 25,000-square-feet. The City expects to net approximately $715,000 over the term of the agreement.
Council approved the EDA after a second reading at its meeting on August 16, 2021.
Public Affairs Officer
614.704.9742 – Cell